Adenylate cyclase 3: a new target for anti-obesity drug development

Obesity Reviews

Volumn 17, Issue 9, 2016, Pages 907-914

  Wu, L ^a   Shen, C ^b   Seed Ahmed, M ^c   Ostenson C G ^d   Gu, H F ^d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenylate cyclase 3; body mass index; obesity

Indexed keywords

ANTIOBESITY AGENT; BETA ADRENERGIC RECEPTOR; CHEMOKINE RECEPTOR CCR9; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; HEME BINDING PROTEIN 1; INOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NEUROPEPTIDE; NEUROPEPTIDE W; PHOSPHATASE; PROTEIN RGS9; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADCY3 GENE; DRUG TARGETING; EPIGENETICS; GENE; GENETIC ASSOCIATION STUDY; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 84982135102     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12430     Document Type: Review

References (44)

1. Reference: Available from: http://www.who.int/mediacentre/factsheets/fs311/en/. 2014
2. Imes CC, Burke LE. The obesity epidemic: the United States as a cautionary tale for the rest of the world. Curr Epidemiol Rep 2014; 1(2): 82–88.
3. Visscher TL, Heitmann BL, Rissanen A, Lahti-Koski M, Lissner L. A break in the obesity epidemic? Explained by biases or misinterpretation of the data? Int J Obes (Lond) 2015; 39(2): 189–98.
4. Yatsuya H, Li Y, Hilawe EH et al. Global trend in overweight and obesity and its association with cardiovascular disease incidence. Circ J 2014; 78(12): 2807–18.
5. Egger G, Dixon J. Beyond obesity and lifestyle: a review of 21st century chronic disease determinants. Biomed Res Int. 2014; 12: 339–345.
6. Goodwin PJ, Stambolic V. Impact of the obesity epidemic on cancer. Annu Rev Med. 2015; 66: 281–96.
7. Després JP. Obesity and cardiovascular disease: weight loss is not the only target. Can J Cardiol 2015; 31(2): 216–22.
8. Anderson Steeves E, Martins PA, Gittelsohn J. Changing the food environment for obesity prevention: key gaps and future directions. Curr Obes Rep 2014; 3(4): 451–458.
9. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014; 5(3): 135–48.
10. Kakkar AK, Dahiya N. Drug treatment of obesity: current status and future prospects. Eur J Intern Med 2015; 26(2): 89–94.
11. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol. 2001; 41: 145–74.
12. Cooper DM. Regulation and organization of adenylyl cyclases and cAMP. Biochem J. 2003; 375: 517–29.
13. Valverde I, Vandermeers A, Anjaneyulu R, Malaisse WJ. Calmodulin activation of adenylate cyclase in pancreatic islets. Science. 1979; 206: 225–7.
14. Dupuis J, Langenberg C, Prokopenko I et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010; 42(2): 105–16.
15. Andersson EA, Pilgaard K, Pisinger C et al. Type 2 diabetes risk alleles near ADCY5, CDKAL1 and HHEX-IDE are associated with reduced birthweight. Diabetologia 2010; 53(9): 1908–16.
16. Nordman S, Abulaiti A, Hilding A et al. Genetic variation of the adenylyl cyclase 3 (AC3) locus and its influence on type 2 diabetes and obesity susceptibility in Swedish men. Int J Obes (Lond) 2008; 32(3): 407–12.
17. Wang H, Wu M, Zhu W et al. Evaluation of the association between the AC3 genetic polymorphisms and obesity in a Chinese Han population. PLoS One 2010; 5(11e13851).
18. Cousminer DL, Berry DJ, Timpson NJ et al. Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and childhood adiposity. Hum Mol Genet 2013; 22(13): 2735–47.
19. Stergiakouli E, Gaillard R, Tavaré JM et al. Genome-wide association study of height-adjusted BMI in childhood identifies functional variant in ADCY3. Obesity (Silver Spring) 2014; 22(10): 2252–9.
20. Warrington NM, Howe LD, Paternoster L et al. A genome-wide association study of body mass index across early life and childhood. Int J Epidemiol 2015; 44(2): 700–12.
21. Felix JF, Bradfield JP, Monnereau C et al. Genome-wide association analysis identifies three new susceptibility loci for childhood body mass index. Hum Mol Genet 2016; 25(2): 389–403.
22. Voisin S, Almén MS, Zheleznyakova GY et al. Many obesity-associated SNPs strongly associate with DNA methylation changes at proximal promoters and enhancers. Genome Med 2015; 7(1): 103.
23. Liu X, Chen Q, Tsai HJ et al. Maternal preconception body mass index and offspring cord blood DNA methylation: exploration of early life origins of disease. Environ Mol Mutagen 2014; 55(3): 223–30.
24. Abdel-Halim SM, Guenifi A, He B et al. Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. Diabetes. 1998; 47: 498–504.
25. Seed Ahmed M, Kovoor A, Nordman S et al. Increased expression of adenylyl cyclase 3 in pancreatic islets and central nervous system of diabetic Goto–Kakizaki rats: a possible regulatory role in glucose homeostasis. Islets 2012; 4(5): 343–8.
26. Östenson CG, Khan A, Abdel-Halim SM et al. Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia 1993; 36(1): 3–8.
27. Gu HF. AC3: a novel gene plays a role in the regulation of body weight. Open Diabetes J 2010; 3: 11–3.
28. Bays H, Scinta W. Adiposopathy and epigenetics: an introduction to obesity as a transgenerational disease. Curr Med Res Opin. 2015; 28: 1–11.
29. Smith CJ, Ryckman KK. Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome. Diabetes Metab Syndr Obes. 2015; 8: 295–302.
30. Dick KJ, Nelson CP, Tsaprouni L et al. DNA methylation and body-mass index: a genome-wide analysis. Lancet 2014 pii: S0140-6736(13)62674-4; 383: 1990–1998.
31. Wang Z, Li V, Chan GC et al. Adult type 3 adenylyl cyclase-deficient mice are obese. PLoS One 2009; 4(9e6979).
32. Pitman JL, Wheeler MC, Lloyd DJ et al. A gain-of-function mutation in adenylate cyclase 3 protects mice from diet-induced obesity. PLoS One 2014; 9(10e110226).
33. Thuillier P, Alavi Z, Kerlan V. Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2015; 8: 483–93.
34. Rendell M. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes. Drugs Today (Barc) 2015; 51(3): 185–96.
35. Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373(1): 11–22.
36. Siraj ES, Williams KJ. Liraglutide in weight management. N Engl J Med 2015; 373(18): 1782.
37. Ando T, Haraguchi A, Matsunaga T et al. Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity. Intern Med 2014; 53(16): 1791–5.
38. Liang Y, Li Z, Liang S et al. Hepatic adenylate cyclase 3 is up-regulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity. Nutr Diabetes 2016; 6 e191.
39. De Matteis R, Arch JR, Petroni ML et al. Immunohistochemical identification of the beta (3)-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int J Obes Relat Metab Disord 2002; 26(11): 1442–50.
40. Hughes TA, Stentz F, Gettys T, Smith SR. Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. Metabolism 2006; 55(1): 26–34.
41. Bogacka I, Gettys TW, de Jonge L et al. The effect of beta-adrenergic and peroxisome proliferator-activated receptor-gamma stimulation on target genes related to lipid metabolism in human subcutaneous adipose tissue. Diabetes Care 2007; 30(5): 1179–86.
42. Reference: Available from: http://string-db.org/version_10/newstring_cgi/show_network_section.pl?limit=0&targetmode=proteins&caller_identity=gene_cards&network_flavor=evidence&identifiers=9606. 2016
43. Waugh JL, Celver J, Sharma M et al. Association between regulator of G protein signaling 9–2 and body weight. PLoS One 2011; 6(11e27984).
44. Shen C, Sharma M, Reid DC et al. A polymorphic microdeletion in the RGS9 gene suppresses PTB binding and associates with obesity. J Diabetes Metab 2014; 5: 437.